

SUPPLEMENTARY DATA

Table 1. Univariate analysis for the prediction of mortality and/or Takotsubo recurrence.			
Variables	HR	95% CI	P-value
Age	1.07	1.05-1.09	<0.001
Female sex	1.17	0.64-2.15	0.601
Smoking	0.50	0.25-0.98	0.044
Hypertension	1.55	1.02-2.38	0.042
Dyslipemia	1.29	0.88-1.87	0.189
Diabetes mellitus	2.15	1.44-3.21	<0.001
Peripheral artery disease	1.36	0.55-3.33	0.502
Coronary artery disease	2.14	1.17-3.92	0.013
Prior stroke	2.39	1.40-4.06	0.001
Prior β-blocker therapy	1.94	1.15-3.26	0.012
COPD	1.48	0.95-2.32	0.085
History of cancer	2.12	1.24-3.62	0.006
Killip ≥ II at admission	2.44	1.68-3.55	<0.001
Atrial fibrillation/flutter	1.94	1.27-2.97	0.002
Bundle brunch block	0.52	0.17-1.64	0.264
Creatinine ≥ 1.5 mg/dL	3.02	1.66-5.50	<0.001
Apical vs Non apical	1.66	1.05-2.61	0.029
Trigger vs Non-trigger			
<i>Emotional Trigger</i>	0.66	0.42-1.04	0.072
<i>Physical Trigger</i>	1.31	0.84-2.06	0.238
Aspirin	0.70	0.48-1.03	0.067
P2Y12 inhibitor	0.72	0.32-1.64	0.433
Oral anticoagulation	1.38	0.87-2.19	0.166
β-blockers	0.86	0.59-1.27	0.444
ACEI/ARB	0.70	0.48-1.02	0.065
Calcium channel blockers	1.36	0.83-2.23	0.219
Nitrates	1.23	0.62-2.44	0.561
Diuretics	1.96	1.29-2.97	0.001
Statins	0.71	0.48-1.03	0.074
Anxiolytic medication	1.14	0.75-1.72	0.540
Antidepressant therapy	1.46	0.86-2.48	0.165

ACEI/ARB: Angiotensin-Converting enzyme inhibitors (ACEI) and angiotensin receptor blockers; CI: Confidence Interval; COPD: Chronic Obstructive Pulmonary Disease; HR: Hazard Ratio.

Table 2. Baseline characteristics after propensity score matching according to the prescription of β-blockers.

Variables	β-blockers (n=202)	Non β-blockers (n=202)	SMD
Age	70.4 ± 11.9	70.8 ± 12.4	-0.033
Female sex	523 (89.9%)	331 (85.3%)	0.016
<i>Smoking</i>	66 (11.3%)	59 (15.2%)	0.047
<i>Hypertension</i>	393 (67.5%)	235 (60.6%)	0.042
<i>Dyslipemia</i>	272 (46.7%)	172 (44.3%)	-0.069
<i>Diabetes mellitus</i>	112 (19.2%)	72 (18.6%)	-0.050
<i>Peripheral artery disease</i>	22 (3.8%)	10 (2.6%)	0.078
<i>Coronary artery disease</i>	40 (6.9%)	30 (7.7%)	0.020
<i>Prior stroke</i>	50 (8.6%)	20 (5.2%)	0.124
Prior β-blocker therapy	72 (12.4%)	19 (4.9%)	0.190
Comorbidities			
<i>COPD</i>	69 (11.9%)	80 (20.6%)	-0.092
<i>History of cancer</i>	54 (9.3%)	54 (13.9%)	-0.017
Presenting characteristics			
<i>Killip ≥ II at admission</i>	176 (30.2%)	142 (36.6%)	-0.129
<i>Atrial fibrillation/flutter</i>	104 (17.9%)	68 (17.5%)	-0.065
<i>Bundle brunch block</i>	38 (6.5%)	16 (4.1%)	0.120
<i>Creatinine > 1.5 mg/dL</i>	35 (6.0%)	12 (3.1%)	0.042
Treatment at discharge			
<i>Aspirin</i>	329 (56.5%)	125 (32.2%)	0.020
<i>P2Y12 inhibitor</i>	49 (8.4%)	18 (4.6%)	0.053
<i>Oral anticoagulation</i>	117 (20.1%)	49 (12.6%)	0.086
<i>ACEI/ARB</i>	426 (73.2%)	168 (43.3%)	-0.056
<i>Calcium channel blockers</i>	38 (6.5%)	47 (12.1%)	-0.080
<i>Nitrates</i>	21 (3.6%)	14 (3.6%)	-0.053
<i>Diuretics</i>	147 (25.3%)	80 (20.6%)	0.011
<i>Statins</i>	345 (59.3%)	132 (34.0%)	0.131
<i>Anxiolytic medication</i>	187 (32.1%)	81 (20.9%)	0.021
<i>Antidepressant therapy</i>	90 (15.5%)	40 (10.3%)	0.027

Values are mean ± standard difference or %.

ACEI/ARB: Angiotensin-Converting enzyme inhibitors (ACEI) and angiotensin receptor blockers; COPD: Chronic Obstructive Pulmonary Disease; SMD: Standardized Mean Difference.